112 related articles for article (PubMed ID: 2156717)
21. Three types of human lung tumour cell lines can be distinguished according to surface expression of endogenous urokinase and their capacity to bind exogenous urokinase.
Schwartz-Albiez R; Heidtmann HH; Wolf D; Schirrmacher V; Moldenhauer G
Br J Cancer; 1992 Jan; 65(1):51-7. PubMed ID: 1310252
[TBL] [Abstract][Full Text] [Related]
22. The inactivation of single-chain urokinase-type plasminogen activator by thrombin on cultured human endothelial cells.
Braat EA; Collen A; Jie AF; Grimbergen JM; Rijken DC
Biochim Biophys Acta; 2000 Sep; 1497(3):351-8. PubMed ID: 10996659
[TBL] [Abstract][Full Text] [Related]
23. [Effect of cyclic AMP and phorbol ester on PAI-2 synthesis in a leukemic cell line PL-21 and on u-PA secretion in a pre-B cell lymphoma cell line RC-K8].
Niiya K; Sakuragawa N
Nihon Rinsho; 1992 Feb; 50(2):325-9. PubMed ID: 1319513
[TBL] [Abstract][Full Text] [Related]
24. Urokinase receptor mRNA level and gene transcription are strongly and rapidly increased by phorbol myristate acetate in human monocyte-like U937 cells.
Lund LR; Rønne E; Roldan AL; Behrendt N; Rømer J; Blasi F; Danø K
J Biol Chem; 1991 Mar; 266(8):5177-81. PubMed ID: 1848242
[TBL] [Abstract][Full Text] [Related]
25. The effect of various vitamin E derivatives on the urokinase-plasminogen activator system of ovine macrophages and neutrophils.
Politis I; Voudouri A; Bizelis I; Zervas G
Br J Nutr; 2003 Feb; 89(2):259-65. PubMed ID: 12575910
[TBL] [Abstract][Full Text] [Related]
26. Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNA.
Dear AE; Costa M; Medcalf RL
FEBS Lett; 1997 Feb; 402(2-3):265-72. PubMed ID: 9037208
[TBL] [Abstract][Full Text] [Related]
27. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
[TBL] [Abstract][Full Text] [Related]
28. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants.
Stephens RW; Pöllänen J; Tapiovaara H; Leung KC; Sim PS; Salonen EM; Rønne E; Behrendt N; Danø K; Vaheri A
J Cell Biol; 1989 May; 108(5):1987-95. PubMed ID: 2523891
[TBL] [Abstract][Full Text] [Related]
29. Identification of urokinase-type plasminogen activator receptor in human endothelial cells and its modulation by phorbol myristate acetate.
Matsumoto H; Ueshima S; Fukao H; Mitsui Y; Matsuo O
Cell Struct Funct; 1995 Dec; 20(6):429-37. PubMed ID: 8825063
[TBL] [Abstract][Full Text] [Related]
30. Functional inhibition of endogenously produced urokinase decreases cell proliferation in a human melanoma cell line.
Kirchheimer JC; Wojta J; Christ G; Binder BR
Proc Natl Acad Sci U S A; 1989 Jul; 86(14):5424-8. PubMed ID: 2501786
[TBL] [Abstract][Full Text] [Related]
31. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
32. Receptor binding and degradation of urokinase-type plasminogen activator by human mesangial cells.
Nguyen G; Li XM; Peraldi MN; Zacharias U; Hagège J; Rondeau E; Sraer JD
Kidney Int; 1994 Jul; 46(1):208-15. PubMed ID: 7933839
[TBL] [Abstract][Full Text] [Related]
33. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas.
Christensen L; Wiborg Simonsen AC; Heegaard CW; Moestrup SK; Andersen JA; Andreasen PA
Int J Cancer; 1996 May; 66(4):441-52. PubMed ID: 8635858
[TBL] [Abstract][Full Text] [Related]
34. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
[TBL] [Abstract][Full Text] [Related]
35. Urokinase (u-PA) and the u-PA receptor. Modulation of in vitro invasiveness of human bladder cancer cell lines.
Hudson MA; McReynold LM
Adv Exp Med Biol; 1999; 462():399-412. PubMed ID: 10599442
[TBL] [Abstract][Full Text] [Related]
36. Cell-surface acceleration of urokinase-catalyzed receptor cleavage.
Høyer-Hansen G; Ploug M; Behrendt N; Rønne E; Danø K
Eur J Biochem; 1997 Jan; 243(1-2):21-6. PubMed ID: 9030717
[TBL] [Abstract][Full Text] [Related]
37. Mitogenic effects of urokinase on melanoma cells are independent of high affinity binding to the urokinase receptor.
Koopman JL; Slomp J; de Bart AC; Quax PH; Verheijen JH
J Biol Chem; 1998 Dec; 273(50):33267-72. PubMed ID: 9837898
[TBL] [Abstract][Full Text] [Related]
38. Nordihydroguaiaretic acid inhibits urokinase synthesis by phorbol myristate acetate-stimulated LLC-PK1 cells.
Rondeau E; Guidet B; Lacave R; Bens M; Sraer J; Nagamine Y; Ardaillou R; Sraer JD
Biochim Biophys Acta; 1990 Nov; 1055(2):165-72. PubMed ID: 2122915
[TBL] [Abstract][Full Text] [Related]
39. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells.
Jensen PH; Christensen EI; Ebbesen P; Gliemann J; Andreasen PA
Cell Regul; 1990 Dec; 1(13):1043-56. PubMed ID: 1966892
[TBL] [Abstract][Full Text] [Related]
40. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2.
Gross TJ; Sitrin RG
J Immunol; 1990 Mar; 144(5):1873-9. PubMed ID: 2307845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
